6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2004
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 8 March, 2004 By Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
8 MARCH 2004

MARSHALL EDWARDS, INC. COMMENCES RENAL CANCER HUMAN
TRIAL OF PHENOXODIOL IN COMBINATION THERAPY

Novogen Limiteds subsidiary, Marshall Edwards, Inc.
(LSE AIM: MSH and Nasdaq: MSHL) has just made the
following announcement to the London Stock Exchanges
Alternative Investment Market.

(Washington, DC and Sydney, Australia) Marshall Edwards,
Inc. has commenced a study that will test the ability
of its investigational anti-cancer drug, phenoxodiol,
to enhance the effect of platinum drugs in patients
with solid cancers, particularly late-stage renal
carcinoma (cancer of the kidney).

The study is being conducted at St George Hospital,
Sydney, Australia. The Principal Investigator
is Paul de Souza MD.

The patients in the study will have late-stage cancers
that are no longer responding to standard chemotherapies.
These chemotherapies include platinum drugs
such as cisplatin and carboplatin, that commonly
are used as first-line therapies for a wide range
of cancers because of their potency. Most patients
eventually become resistant to such drugs so
overcoming that resistance has become an urgent
medical need.

In the laboratory, phenoxodiol has shown a potent
ability in cancer cells to reverse chemo-resistance
to drugs such as cisplatin and carboplatin.
The basis of this reversal is thought to be the
ability of phenoxodiol to remove blocking proteins
such as XIAP(X-linked Inhibitor of Apoptosis Protein)
which are over-expressed in cancer cells.

In this study, phenoxodiol will be administered in
the oral dosage form. Patients will take capsules
of phenoxodiol, in one of four dose strata, three
times a day, for treatment cycles of 12 weeks.
Patients will also either receive cisplatin or
carboplatin once weekly at a fixed dose.

One of the main objectives of the study is to
determine the appropriate dose level of phenoxodiol
for renal cancer. Studies have shown that
phenoxodiol is likely to be more effective at lower,
rather than higher doses for a wide range of applications.

Dr. Graham Kelly, Executive Chairman of Marshall Edwards,
Inc., said, Phenoxodiol is an exciting prospect for
the reversal of chemo-resistance in late-stage cancers
where patients have no therapeutic options remaining.
This study is one of a number where we are
testing that proposition.

Preliminary studies to date indicate that phenoxodiol
may enhance ability of drugs such as platinums
to kill cancer cells, without impacting normal cells.
This study hopes to confirm that.

Another important objective is to confirm the
therapeutic benefit of phenoxodiol combinational
therapy in patients particularly those with
late-stage renal carcinoma (cancer of the kidney).
Based on our clinical experience to date, we have
good reason to believe that phenoxodiol has
considerable potential in this deadly form of
cancer, Kelly added.

Marshall Edwards, Inc., is pursuing a dual strategy
of developing phenoxodiol for the treatment of both
early-stage cancers and late-stage cancers.
The strategy in early-stage cancers of using
phenoxodiol as a monotherapy is intended to result
in the killing of cancer cells before they have had
a chance to develop the pro-survival techniques,
involving apoptosis blocking proteins, that
characterize many late-stage cancers. The strategy
being employed for the late-stage cancers is to
use phenoxodiol in combination with standard drugs
such as paclitaxel and cisplatin.

Phenoxodiol was developed by Novogen Limited
(Nasdaq: NVGN; ASX: NRT) and licensed to Marshall
Edwards, Inc. It is an investigational anti-cancer
drug that has yet to receive marketing approval by
regulatory authorities.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995. You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Dr Graham Kelly,
Chairman, Marshall Edwards, Inc., + 61.2.9878 0088